KBC Securities - Sequana Medical (SEQUA) Sequana Medical FIRST LOOK: Additional funding extends runway to YE25

Report

KBC Securities

Jacob Mekhael

Sequana Medical FIRST LOOK: Additional funding extends runway to YE25

Sequana announced that it has secured additional financing including a €4m convertible, and a facility agreement with GEM up to €20m, as well as amending the terms of the Kreos and PMV loans. The new cash provides funding to YE25, and gives the company breathing room to progress towards US commercialisation of the alfapump expected in 3Q25. We plan to incorporate this new financing in a future model update. BUY reiterated.

18/03/2025 1 EN

Underlying

Sequana Medical

Sequana Medical NV. Sequana Medical NV is a Belgium-based company, which manufactures medical devices. The Company focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.

See profile

BE0974340722 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Other Reports on these Companies

KBC Securities

Morning Notes : SEQUA BB, SOLB BB

: SEQUA BB, SOLB BB

March 18, 2025 March 18, 2025 1 EN

KBC Securities

Morning Notes : SEQUA BB

: SEQUA BB

January 24, 2025 January 24, 2025 1 EN

MaaT Pharma FIRST LOOK: Positive DSMB review for lead product MaaT013 in aGvHD

MaaT announced that the independent data safety monitoring board (DSMB) completed its final safety assessment of the pivotal phase 3 (ARES) trial of MaaT013 in 3L aGvHD, which was in line with previous evaluations confirming the favourable benefit/risk ratio of the product. As a reminder, MaaT013 met its primary endpoint in the phase 3 (ARES) trial, and results presented in January 2025 demonstrated a 28 day GI-ORR of 62%, which came in above expectations. Looking ahead, we look forward to the regulatory submission in the EU planned for June 2025. We reiterate our € 18 TP and Buy rating.

11h / 52m 11h / 52m 1 EN

Sharad Kumar S.P

Sharad Kumar S.P

Gimv Bart Troubleyn to lead Gimv Anchor

Following Gimv's CMD (Jan'25) during which it announced its new strategy, deeper collaboration with WorxInvest, and launched ‘Gimv Anchor', Gimv has appointed Bart Troubleyn as the Head of Gimv Anchor (from mid-April onwards). Bart will also become a member of Gimv's Executive Committee. In his role, Bart will be working closely with all Managing Partners and teams of individual Gimv platforms in terms of both deal sourcing and in further strengthening the active value creation across platforms. Gimv continues to trade at a discount of 26%+ to its NAV while pre-pandemic, the stock traded at a ...

11h / 57m 11h / 57m 1 EN

Jacob Mekhael

Jacob Mekhael

UCB FIRST LOOK: New data on pyrimidine nucleoside therapy in TK2d at MDA

UCB presented results from studies involving doxecitine (dC) and doxribtimine (dT) (pyrimidine nucleoside therapy) in people living with thymidine kinase 2 deficiency (TK2d), at the MDA Clinical and Scientific Conference, being held 16-19 March in Dallas. The improvements in survival and functional outcomes highlight the potential of doxecitine and doxribtimine in treating TK2d, which is an ultra-rare genetic mitochondrial disease with no approved therapies, and has a prevalence of 1.64/1m people. Doxecitine and doxribtimine is currently under regulatory review in the US and EU, and we model p...

12h / 2m 12h / 2m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Sequana Medical FIRST LOOK: Additional funding extends runway to YE25

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : SEQUA BB, SOLB BB

Morning Notes : SEQUA BB

MaaT Pharma FIRST LOOK: Positive DSMB review for lead product MaaT013 in aGvHD

Gimv Bart Troubleyn to lead Gimv Anchor

UCB FIRST LOOK: New data on pyrimidine nucleoside therapy in TK2d at MDA

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe